Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight and obesity
Portfolio Pulse from
Zealand Pharma and Roche have entered a collaboration to co-develop and co-commercialize petrelintide for treating overweight and obesity. Zealand Pharma will receive up to $5.3 billion, including $1.65 billion upfront. Profits and losses will be shared equally in the U.S. and Europe.
March 12, 2025 | 6:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Roche collaborates with Zealand Pharma to develop petrelintide, sharing profits equally in the U.S. and Europe. Roche will receive $350 million for CT-388 contribution.
Roche's collaboration with Zealand Pharma on a promising obesity treatment could enhance its product offerings and market position, potentially boosting its stock.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Zealand Pharma partners with Roche to develop petrelintide, receiving up to $5.3 billion. This includes $1.65 billion upfront, with profits shared equally in the U.S. and Europe.
The collaboration with Roche and the significant financial inflow from the agreement are likely to positively impact Zealand Pharma's stock. The partnership enhances their product pipeline and financial stability.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100